ANNUAL REPORT QUARTERLY REPORTS ANALYST BRIEFING OPERATIONAL HIGHLIGHTS FINANCIAL HIGHLIGHTS RATIO ANALYSIS
Year
2025
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2025

Quarter 1

Not Available

2025
QUARTER 1
2025

Quarter 2

Not Available

2025
QUARTER 2
2025

Quarter 3

Not Available

2025
QUARTER 3
2025

Quarter 4

2025
QUARTER 4
Quarterly Report

Quarterly Report

View Quarterly Report

  1. Licensed beds are approved number of beds by the Ministry of Health while operational beds is an internal measure which includes licensed beds utilised for patients.

  2. Represents the total number of overnight inpatients admitted.

  3. Represents the average number of days an overnight inpatient stays.

  4. Represents the percentage of hospital operational/overnight beds occupied by inpatients. (Occupancy rate may be lower due to new hospitals that are in the ramp up stage)

REVENUE
RM 2,200.39 bil
Financial Period Ended 01 January 2025

  1. Being earnings before interest, tax, depreciation, amortisation

Financial information for the FYEs 31 December 2020 and 2021 is presented on a pro-forma basis as if our Company, which was incorporated on 5 January 2021, had existed and consolidated the results of all the subsidiaries within our Group as from 1 January 2020.

  1. Adjusted EBITDA is calculated as profit, plus income tax expense, finance costs and depreciation and amortisation, less finance and other distribution income, gain on lease reassessment and rectification claim.

    (1) EXCLUDES ONE-OFF / EXCEPTIONAL ITEMS
    2025
    (RM mil)
    2024
    (RM mil)
    2023
    (RM mil)
    2022
    (RM mil)
    2021
    (RM mil)
    Gain on Lease Reassessment
    -
    -
    (0.17)
    (57.53)
    -
    Rectification Claim
    (11.20)
    (11.20)
    -
    -
    -
    Impact on EBITDA
    (11.20)
    (11.20)
    (0.17)
    (57.53)
    -
    Impact on PAT
    (8.51)
    (8.51)
    (0.13)
    (43.72)
    -

  2. Adjusted PBT is calculated as profit before tax less gain on lease reassessment and rectification claim.

  1. For the purpose of EPS computation, the weighted average number of ordinary shares in issue for all periods presented is based on the enlarged issued share capital of 11,500,165,558 ordinary shares upon the Listing (presented in ’000), in order to provide a consistent and comparable basis across periods.

  2. Net assets per ordinary share is calculated based on the Company’s enlarged share capital of 11,500,165,558 ordinary shares upon the Listing.